✦ LIBER ✦

A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects

✍ Scribed by Christoph Hatz; Frank von Sonnenburg; Daniela Casula; Maria Lattanzi; Geert Leroux-Roels

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of an MF59®-ad

✍ Timo Vesikari; Aino Forstén; Karl-Heinz Herbinger; Giovanni Della Cioppa; Jenny 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 497 KB

Assessment of the immunogenicity and saf

✍ Hiroyuki Fukase; Hidetoshi Furuie; Yuji Yasuda; Ryoya Komatsu; Kenji Matsushita; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 397 KB

Immunogenicity, safety and tolerability

✍ Susanna Esposito; Emanuela D’Angelo; Cristina Daleno; Francesco Peia; Alessia Sc 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 122 KB

Priming for Pandemic Influenza: Antigen-

✍ V.F.H. Brauer; F. Laghi-Pasini; P.L. Capecchi; C. Gentile; P. di Giovanni; T. St 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Dose ranging of adjuvant and antigen in

✍ Wendy Keitel; Nicola Groth; Maria Lattanzi; Michaela Praus; Anne Katrin Hilbert; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 950 KB

Safety and immunogenicity of a trivalent

✍ M. Loebermann; G. Anders; G. Brestrich; C. Fritzsche; S. Klammt; D. Boršo; S. Fr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 267 KB